Adverum Biotechnologies (ADVM) Competitors $4.74 +0.04 (+0.85%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ADVM vs. SANA, YMAB, KALV, IGMS, GHRS, RGNX, TSHA, ALMS, AKBA, and CYRXShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Sana Biotechnology (SANA), Y-mAbs Therapeutics (YMAB), KalVista Pharmaceuticals (KALV), IGM Biosciences (IGMS), GH Research (GHRS), REGENXBIO (RGNX), Taysha Gene Therapies (TSHA), Alumis (ALMS), Akebia Therapeutics (AKBA), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Sana Biotechnology Y-mAbs Therapeutics KalVista Pharmaceuticals IGM Biosciences GH Research REGENXBIO Taysha Gene Therapies Alumis Akebia Therapeutics Cryoport Sana Biotechnology (NASDAQ:SANA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Is SANA or ADVM more profitable? Adverum Biotechnologies' return on equity of -65.14% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Sana BiotechnologyN/A -84.22% -44.97% Adverum Biotechnologies N/A -65.14%-40.52% Does the MarketBeat Community favor SANA or ADVM? Adverum Biotechnologies received 351 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 60.20% of users gave Adverum Biotechnologies an outperform vote while only 58.06% of users gave Sana Biotechnology an outperform vote. CompanyUnderperformOutperformSana BiotechnologyOutperform Votes1858.06% Underperform Votes1341.94% Adverum BiotechnologiesOutperform Votes36960.20% Underperform Votes24439.80% Which has stronger valuation & earnings, SANA or ADVM? Adverum Biotechnologies has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSana BiotechnologyN/AN/A-$283.26M-$1.40-1.18Adverum Biotechnologies$1M98.60-$117.17M-$5.99-0.79 Does the media prefer SANA or ADVM? In the previous week, Adverum Biotechnologies had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Adverum Biotechnologies and 0 mentions for Sana Biotechnology. Adverum Biotechnologies' average media sentiment score of 0.70 beat Sana Biotechnology's score of 0.00 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Overall Sentiment Sana Biotechnology Neutral Adverum Biotechnologies Positive Do analysts prefer SANA or ADVM? Sana Biotechnology currently has a consensus target price of $13.50, indicating a potential upside of 718.18%. Adverum Biotechnologies has a consensus target price of $27.83, indicating a potential upside of 487.20%. Given Sana Biotechnology's higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Adverum Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders & institutionals have more ownership in SANA or ADVM? 88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 31.1% of Sana Biotechnology shares are held by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, SANA or ADVM? Sana Biotechnology has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. SummaryAdverum Biotechnologies beats Sana Biotechnology on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.60M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.7946.7391.3417.19Price / Sales98.60411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book0.573.894.794.78Net Income-$117.17M-$42.21M$120.07M$225.60M7 Day Performance-11.73%-2.14%-1.90%-1.23%1 Month Performance-18.28%4.21%11.45%3.37%1 Year Performance-38.52%18.40%30.63%16.58% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.215 of 5 stars$4.74+0.9%$27.83+487.2%-40.0%$98.60M$1M-0.79190Analyst DowngradeNews CoverageSANASana Biotechnology2.0915 of 5 stars$1.97+4.2%$13.50+585.3%-59.8%$439.84MN/A-1.35328YMABY-mAbs Therapeutics2.2471 of 5 stars$9.81+4.0%$20.89+112.9%+35.7%$439.39M$84.82M-17.46150KALVKalVista Pharmaceuticals3.9512 of 5 stars$8.87+2.1%$24.00+170.6%-24.0%$438.36MN/A-2.39150Analyst ForecastIGMSIGM Biosciences4.5517 of 5 stars$7.34+2.4%$17.75+141.8%-12.2%$436.47M$2.92M-2.11190News CoverageGHRSGH Research1.1295 of 5 stars$8.22+6.2%$35.67+333.9%+28.8%$427.67MN/A-9.8010RGNXREGENXBIO4.5991 of 5 stars$8.54+3.1%$35.27+313.0%-58.4%$423.11M$84.33M-1.70344TSHATaysha Gene Therapies3.6226 of 5 stars$2.01-2.9%$6.63+229.6%+30.3%$411.93M$15.45M3.29180ALMSAlumisN/A$8.58+2.3%$26.83+212.7%N/A$405.17MN/A0.00N/AAnalyst ForecastLockup ExpirationNews CoveragePositive NewsAKBAAkebia Therapeutics3.3979 of 5 stars$1.86+0.3%$7.50+304.3%+52.5%$404.73M$169.88M-8.15167News CoverageCYRXCryoport3.0208 of 5 stars$7.70+0.1%$12.50+62.3%-49.8%$380.62M$226.11M-2.321,170Analyst ForecastGap Down Related Companies and Tools Related Companies SANA Alternatives YMAB Alternatives KALV Alternatives IGMS Alternatives GHRS Alternatives RGNX Alternatives TSHA Alternatives ALMS Alternatives AKBA Alternatives CYRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADVM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts